View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 9, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Perrigo Co: 1 director

A director at Perrigo Co maiden bought 1,000 shares at 23.200USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 6, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635...

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on September 2, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 82,950 shares of common stock to seven (7) new employees under the Company...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: September 4, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Smithfield Foods Announces Pricing of Upsized Secondary Offering of Co...

Smithfield Foods Announces Pricing of Upsized Secondary Offering of Common Stock SMITHFIELD, Va., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Smithfield Foods, Inc. (Nasdaq: SFD) (the “Company”), an American food company and an industry leader in value-added packaged meats and fresh pork, today announced the pricing of a secondary public offering of 19,531,698 shares of common stock of the Company sold by SFDS UK Holdings Limited, the principal shareholder of the Company, at a price to the public of $23.25 per share. In addition, the selling shareholder has granted the underwriters a 30-day option...

 PRESS RELEASE

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl ...

Kura Oncology to Host Virtual Investor and Analyst Events on Farnesyl Transferase Inhibitor Program September 16 event to highlight preclinical data on the combination of FTI agents with multiple classes of targeted therapies October 18 event to review clinical data from the ESMO Congress 2025, including first clinical data from KO-2806 SAN DIEGO, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for cancer, today announced it will host two virtual investor and analy...

 PRESS RELEASE

Smithfield Foods Announces Launch of Secondary Offering of Common Stoc...

Smithfield Foods Announces Launch of Secondary Offering of Common Stock SMITHFIELD, Va., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Smithfield Foods, Inc. (Nasdaq: SFD) (the “Company”), an American food company and an industry leader in value-added packaged meats and fresh pork, today announced the launch of a secondary public offering of 16,000,000 shares of common stock of the Company to be sold by SFDS UK Holdings Limited, the principal shareholder of the Company. In addition, the selling shareholder intends to grant the underwriters a 30-day option to purchase up to 2,400,000 additional share...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: September 2, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Wedbush Research
  • Wedbush Research
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong
Jonathan Moreland
  • Jonathan Moreland

Monthly Insider Special Screens: September 1, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

nsiderInsights Weekly Report: August 30, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Kura Oncology to Participate in Three Upcoming Investor Conferences

Kura Oncology to Participate in Three Upcoming Investor Conferences SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that management is scheduled to participate in three investor conferences in September. Cantor Global Health ConferenceThursday, September 4, 20258:35 a.m. ET / 5:35 a.m. PT H.C. Wainwright 27th Annual Global Investment ConferenceMonday, September 8, 20251:00 p.m. ET / 10:00 a.m. PT Morgan Stanle...

 PRESS RELEASE

Nautilus Biotechnology to Participate in Upcoming September Investor C...

Nautilus Biotechnology to Participate in Upcoming September Investor Conferences SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences. Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NYManagement is scheduled to participate in a fireside chat on Monday, September 8h at 10:50 a.m. Pacific Time / 1:50 p.m. Eastern Time. Q3 Investor Summit Group Virtual ConferenceManag...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: August 25, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: August 22, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: August 20, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch